Active Ingredients: Isotretinoin
Patients at increased risk for early relapse included younger patients with acne of relatively recent onset, those with truncal acne, and women with polycystic ovary syndrome.
In our study, relapse rate had not any relation with patient's weight, age, and anatomical location of lesions. Safety was assessed during the study by the reporting of adverse events.
The most common side-effects in our study were mild cheilitis in 93 patients 66. The observed side-effects were mild, and only 6 patients discontinued study medication because of severe adverse events.
Isotretinoin can cause variant side-effects; mucocutaneous side-effects are the most common, experienced by virtually all patients.
Epistaxis only seen in conventional group but in our study. Elevated liver function test results, and increase in serum lipid profiles was mild, and usually returned to normal within 6-8 weeks, despite continuation of treatment.
The present study showed that low dose 20 mg daily isotretiinoin represents a well-tolerated and efficient alternative to the standard 0.
The only pitfall is it is longer than 10 months duration of treatment period.
The low frequency of adverse side-effects in this study, suggest that most side effects of the drug, are dose dependent; and the most serious side effects of the drug can be reduced significantly by using lower doses.
Hence, we recommend this low dose therapy for treatment of moderate to severe scar prone acne.
A large, prospective randomized comparative study is needed to establish the definitive response and tolerance of this protocol.
Footnotes Conflict of Interest: None declared. Prevalence of facial acne vulgaris in late adolescence and in adults.
Br Med J. Oral isotretinoin is as effective as a combination of oral isotretinoin and topical anti-acne agents in nodulocystic acne.
Indian J Dermatol Venereol Leprol. Roaccutane treatment guidelines: Results of an international survey. Isotretinoin versus placebo in the treatment of cystic acne.
A randomized double-blind study. J Am Acad Dermatol.